| 13:55 | Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer's .. |  |
| 12:09 | Neurocrine Biosciences Inc: Other Events (form 8-K) | |
| 21/03 | Neurocrine Biosciences to Present at the Stifel 2023 CNS Days | |
| 10/03 | Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA Ca.. | |
| 09/03 | Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Pub.. | |
| 09/03 | Neurocrine Biosciences, Inc. Announces New Data from RE-KINECT Study Published in the J.. | |
| 09/03 | Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (.. | |
| 09/03 | Neurocrine Biosciences, Inc. Presents Data from Three in Vitro Dissolution Studies Expl.. | |
| 08/03 | Neurocrine Biosciences to Participate at Investor Conferences in March | |
| 06/03 | Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of IN.. | |
| 03/03 | Neurocrine Biosciences, Inc. Presents Data Analyzing the Long-Term Outcomes of Treating.. | |
| 24/02 | Neurocrine Biosciences: Purchase Agreement - Form 8-K | |
| 24/02 | Neurocrine Biosciences Inc: Other Events (form 8-K) | |
| 14/02 | Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Dis.. | |
| 14/02 | Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collabora.. | |
| 10/02 | Neurocrine Biosciences Inc: Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye.. | |
| 09/02 | NEUROCRINE BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition.. | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 09/02 | Insider Sell: Neurocrine Biosciences | |
| 07/02 | Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference | |
| 07/02 | Jerome returns in the second week | |
| 06/02 | Neurocrine Biosciences Q4 Non-GAAP Earnings, Revenue Rise | |
| 06/02 | Neurocrine Biosciences, Inc. Provides Revenue Guidance for the Year 2023 | |
| 06/02 | Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q4 Revenue $412M, vs. Street Est o.. | |
| 06/02 | Neurocrine: Q4 Earnings Snapshot | |
| 06/02 | Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Y.. | |
| 06/02 | Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q4 EPS $1.24, vs. Street Est of $1.4.. | |
| 06/02 | Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Pro.. | |
| 06/02 | North American Morning Briefing: Payrolls -3- | |
| 02/02 | Insider Sell: Neurocrine Biosciences | |
| 02/02 | Insider Sell: Neurocrine Biosciences | |
| 02/02 | Insider Sell: Neurocrine Biosciences | |
| 17/01 | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year.. | |
| 09/01 | Neurocrine Biosciences, Voyager Therapeutics to Develop, Commercialize Gene Therapies f.. | |
| 09/01 | Neurocrine Biosciences Inc: Entry into a Material Definitive Agreement, Financial Stateme.. | |
| 09/01 | Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Devel.. | |
| 09/01 | Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Devel.. | |
| 06/01 | Insider Sell: Neurocrine Biosciences | |
| 06/01 | Insider Sell: Neurocrine Biosciences | |
| 03/01 | Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference | |
| 2022 | Neurocrine Biosciences Says US FDA Accepts Supplemental NDA for Valbenazine for Chorea .. | |
| 2022 | Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for.. | |
| 2022 | Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Applicati.. | |
| 2022 | Neurocrine Biosciences Says Prospective Epilepsy Drug Did Not Meet Endpoint in Mid-Stag.. | |
| 2022 | Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Pati.. | |
| 2022 | Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Pati.. | |
| 2022 | Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediat.. | |
| 2022 | Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediat.. | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Neurocrine Biosciences to Present at Upcoming Healthcare Conferences | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating .. | |
| 2022 | Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating .. | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Diurnal Shares Delisted After Neurocrine Biosciences Takeover | |
| 2022 | NEUROCRINE BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition.. | |
| 2022 | Top Midday Gainers | |
| 2022 | Neurocrine Biosciences Q3 Non-GAAP Earnings, Revenue Rise | |
| 2022 | Diurnal's Takeover Scheme By US-based Neurocrine Biosciences Becomes Effective | |
| 2022 | Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q3 EPS $1.08, vs. Street Est of $1.1.. | |
| 2022 | Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q3 Revenue $387.9M, vs. Street Est o.. | |
| 2022 | Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q3 EPS $1.08, vs. Street Est of $1.1.. | |
| 2022 | Neurocrine: Q3 Earnings Snapshot | |
| 2022 | Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 ING.. | |
| 2022 | Neurocrine Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Mo.. | |
| 2022 | Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022 | |
| 2022 | Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) comple.. | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility | |
| 2022 | Neurocrine Biosciences Starts Phase 2 Trial of NBI-1117568 to Treat Schizophrenia | |
| 2022 | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adult.. | |
| 2022 | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adult.. | |
| 2022 | Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics .. | |
| 2022 | Neurocrine Biosciences, Inc. Presents Real-World Parkinson's Disease Patient Characteri.. | |
| 2022 | Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antip.. | |
| 2022 | Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Fina.. | |
| 2022 | Insider Sell: Neurocrine Biosciences | |
| 2022 | Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer | |
| 2022 | Neurocrine Biosciences, Inc. Announces That Dr. Ingrid Delaet Will Join the Company's E.. | |
| 2022 | Capitulation ahead? | |
| 2022 | Analyst recommendations: Anglo American, Aveva, BP pc, Costco, F.. | |
| 2022 | Neurocrine Biosciences Presents INGREZZA Data on Sustained Treatment Response at Psych .. | |
| 2022 | Neurocrine Biosciences Says Study Showed 'Sustained' Improvement With Valbenazine in Ad.. | |
| 2022 | Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Res.. | |
| 2022 | Neurocrine Biosciences Presents INGREZZA(R) (valbenazine) Data on Sustained Treatment R.. | |
| 2022 | Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS Capsules Effect on CO.. | |
| 2022 | Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Educati.. | |
| 2022 | Neurocrine Biosciences, Inc. Announces to Present Study Findings on Evolving Tardive Dy.. | |
| 2022 | Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Nederlands (Nederland)
Nederlands (België)
Rapporto
